143 related articles for article (PubMed ID: 25831840)
1. [Bortezomib-based triple combinations (VCD, PAD) for untreated patients with multiple myeloma].
Izumi T
Nihon Rinsho; 2015 Feb; 73 Suppl 2():646-8. PubMed ID: 25831840
[No Abstract] [Full Text] [Related]
2. [PAD regimen for relapsed or refractory patients with multiple myeloma].
Zhang YQ; Liang R; Bai QX; Zhang T; Yang L; Wang YW; Wang WQ; Gu HT; Shu MM; Zhu HF; Bai YN; Chen XQ
Zhonghua Xue Ye Xue Za Zhi; 2009 Apr; 30(4):260-3. PubMed ID: 19731828
[TBL] [Abstract][Full Text] [Related]
3. Long-term survival with cyclophosphamide, bortezomib and dexamethasone induction therapy in patients with newly diagnosed multiple myeloma.
Reeder CB; Reece DE; Kukreti V; Mikhael JR; Chen C; Trudel S; Laumann K; Vohra H; Fonseca R; Bergsagel PL; Leis JF; Tiedemann R; Stewart AK
Br J Haematol; 2014 Nov; 167(4):563-5. PubMed ID: 24974945
[No Abstract] [Full Text] [Related]
4. Bortezomib plus melphalan and prednisone for multiple myeloma.
Tsubokura M; Kami M; Komatsu T
N Engl J Med; 2008 Dec; 359(24):2613; author reply 2613-4. PubMed ID: 19090031
[No Abstract] [Full Text] [Related]
5. Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in newly diagnosed myeloma.
Mai EK; Bertsch U; Dürig J; Kunz C; Haenel M; Blau IW; Munder M; Jauch A; Schurich B; Hielscher T; Merz M; Huegle-Doerr B; Seckinger A; Hose D; Hillengass J; Raab MS; Neben K; Lindemann HW; Zeis M; Gerecke C; Schmidt-Wolf IG; Weisel K; Scheid C; Salwender H; Goldschmidt H
Leukemia; 2015 Aug; 29(8):1721-9. PubMed ID: 25787915
[TBL] [Abstract][Full Text] [Related]
6. Bortezomib plus melphalan and prednisone for multiple myeloma.
Avvisati G
N Engl J Med; 2008 Dec; 359(24):2613; author reply 2613-4. PubMed ID: 19090032
[No Abstract] [Full Text] [Related]
7. Multiple significant bortezomib-related toxicities in one patient: case report and literature review.
Waller JM; Moretto JC; Knopf KB
Clin Lymphoma Myeloma; 2009 Jun; 9(3):E1-4. PubMed ID: 19525183
[TBL] [Abstract][Full Text] [Related]
8. Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma.
Kumar S; Flinn I; Richardson PG; Hari P; Callander N; Noga SJ; Stewart AK; Turturro F; Rifkin R; Wolf J; Estevam J; Mulligan G; Shi H; Webb IJ; Rajkumar SV
Blood; 2012 May; 119(19):4375-82. PubMed ID: 22422823
[TBL] [Abstract][Full Text] [Related]
9. PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma.
Oakervee HE; Popat R; Curry N; Smith P; Morris C; Drake M; Agrawal S; Stec J; Schenkein D; Esseltine DL; Cavenagh JD
Br J Haematol; 2005 Jun; 129(6):755-62. PubMed ID: 15953001
[TBL] [Abstract][Full Text] [Related]
10. Once- versus twice-weekly bortezomib induction therapy with CyBorD in newly diagnosed multiple myeloma.
Reeder CB; Reece DE; Kukreti V; Chen C; Trudel S; Laumann K; Hentz J; Pirooz NA; Piza JG; Tiedemann R; Mikhael JR; Bergsagel PL; Leis JF; Fonseca R; Stewart AK
Blood; 2010 Apr; 115(16):3416-7. PubMed ID: 20413666
[No Abstract] [Full Text] [Related]
11. The safety and efficacy of bortezomib in relapsed multiple myeloma.
Jagannath S
Clin Adv Hematol Oncol; 2006 May; 4(5):2-3; discussion 8; suppl 13. PubMed ID: 16830423
[No Abstract] [Full Text] [Related]
12. A new standard of care in newly diagnosed multiple myeloma.
Richardson PG
Lancet; 2010 Dec; 376(9758):2043-4. PubMed ID: 21146204
[No Abstract] [Full Text] [Related]
13. [Efficacy comparison between standard and reduced doses of bortezomib combined with adriamycin and dexamethasone in the treatment of patients with multiple myeloma].
Gu HT; Shu MM; Gao GX; Dong BX; Liang R; Yang L; Bai QX; Zhang T; Zhang YQ; Chen XQ
Zhonghua Xue Ye Xue Za Zhi; 2013 Jul; 34(7):622-5. PubMed ID: 23906459
[TBL] [Abstract][Full Text] [Related]
14. Bortezomib, doxorubicin and dexamethasone (PAD) front-line treatment of multiple myeloma: updated results after long-term follow-up.
Popat R; Oakervee HE; Hallam S; Curry N; Odeh L; Foot N; Esseltine DL; Drake M; Morris C; Cavenagh JD
Br J Haematol; 2008 May; 141(4):512-6. PubMed ID: 18371113
[TBL] [Abstract][Full Text] [Related]
15. Phase 2 study of two sequential three-drug combinations containing bortezomib, cyclophosphamide and dexamethasone, followed by bortezomib, thalidomide and dexamethasone as frontline therapy for multiple myeloma.
Bensinger WI; Jagannath S; Vescio R; Camacho E; Wolf J; Irwin D; Capo G; McKinley M; Potts P; Vesole DH; Mazumder A; Crowley J; Becker P; Hilger J; Durie BG
Br J Haematol; 2010 Feb; 148(4):562-8. PubMed ID: 19919652
[TBL] [Abstract][Full Text] [Related]
16. Schedule dependent cytotoxicity of bortezomib and melphalan in multiple myeloma.
Popat R; Maharaj L; Oakervee H; Cavenagh J; Joel S
Br J Haematol; 2013 Jan; 160(1):111-4. PubMed ID: 23078038
[No Abstract] [Full Text] [Related]
17. [The efficacy and safety of PAD and VAD regimens for untreated multiple myeloma].
Zhao Y; Dou LP; Wang SH; Bo J; Wang QS; Huang WR; Jing Y; Gao CJ; Li HH; Zhu HY; Han XP; Yu L
Zhonghua Nei Ke Za Zhi; 2010 Sep; 49(9):762-4. PubMed ID: 21092447
[TBL] [Abstract][Full Text] [Related]
18. [Effectiveness of bortezomib and bortezomib-containing programs for the treatment of recurrent and resistant multiple myeloma].
Mitina TA; Golenkov AK; Kataeva EV; Lutskaia TD; Trifonova EV; Klinushkina EF
Ter Arkh; 2010; 82(7):57-61. PubMed ID: 20853611
[TBL] [Abstract][Full Text] [Related]
19. Low-dose acyclovir prophylaxis for bortezomib-induced herpes zoster in multiple myeloma patients.
Minarik J; Pika T; Bacovsky J; Langova K; Scudla V
Br J Haematol; 2012 Oct; 159(1):111-3. PubMed ID: 22816982
[No Abstract] [Full Text] [Related]
20. Bortezomib subcutaneous injection in combination regimens for myeloma or systemic light-chain amyloidosis: a retrospective chart review of response rates and toxicity in newly diagnosed patients.
Shah G; Kaul E; Fallo S; Cossor F; Smith H; Sprague K; Klein A; Miller K; Comenzo R
Clin Ther; 2013 Oct; 35(10):1614-20. PubMed ID: 24075726
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
